206 related articles for article (PubMed ID: 20133893)
1. Long FLT3 internal tandem duplications and reduced PML-RARα expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients.
Chillón MC; Santamaría C; García-Sanz R; Balanzategui A; Sarasquete ME; Alcoceba M; Marín L; Caballero MD; Vidriales MB; Ramos F; Bernal T; Díaz-Mediavilla J; García de Coca A; Peñarrubia MJ; Queizán JA; Giraldo P; San Miguel JF; González M
Haematologica; 2010 May; 95(5):745-51. PubMed ID: 20133893
[TBL] [Abstract][Full Text] [Related]
2. Inferior prognostic outcome in acute promyelocytic leukemia with alterations of FLT3 gene.
Yoo SJ; Park CJ; Jang S; Seo EJ; Lee KH; Chi HS
Leuk Lymphoma; 2006 Sep; 47(9):1788-93. PubMed ID: 17064989
[TBL] [Abstract][Full Text] [Related]
3. [Prevalence and clinical significance of FLT3 mutations in acute promyelocytic leukemia].
Xue MX; Qiu HY; Feng YF; Zhu ZL; Chang WR; Liang JY; Chen SN; Cen JN; Xue YQ; Liu YJ; Sun AN; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2008 Nov; 29(11):757-61. PubMed ID: 19176014
[TBL] [Abstract][Full Text] [Related]
4. Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study.
Lucena-Araujo AR; Kim HT; Jacomo RH; Melo RA; Bittencourt R; Pasquini R; Pagnano K; Fagundes EM; Chauffaille Mde L; Chiattone CS; Lima AS; Ruiz-Argüelles G; Undurraga MS; Martinez L; Kwaan HC; Gallagher R; Niemeyer CM; Schrier SL; Tallman MS; Grimwade D; Ganser A; Berliner N; Ribeiro RC; Lo-Coco F; Löwenberg B; Sanz MA; Rego EM
Ann Hematol; 2014 Dec; 93(12):2001-10. PubMed ID: 24981688
[TBL] [Abstract][Full Text] [Related]
5. Cytogenetic and FMS-like tyrosine kinase 3 mutation analyses in acute promyelocytic leukemia patients.
Yaghmaie M; Alimoghaddam K; Mozdarani H; Ghavamzadeh A; Hajhashemi M; Aznab M; Ghaffari SH
Iran Biomed J; 2012; 16(1):10-7. PubMed ID: 22562027
[TBL] [Abstract][Full Text] [Related]
6. Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol.
Noguera NI; Breccia M; Divona M; Diverio D; Costa V; De Santis S; Avvisati G; Pinazzi MB; Petti MC; Mandelli F; Lo Coco F
Leukemia; 2002 Nov; 16(11):2185-9. PubMed ID: 12399960
[TBL] [Abstract][Full Text] [Related]
7. Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group.
Callens C; Chevret S; Cayuela JM; Cassinat B; Raffoux E; de Botton S; Thomas X; Guerci A; Fegueux N; Pigneux A; Stoppa AM; Lamy T; Rigal-Huguet F; Vekhoff A; Meyer-Monard S; Ferrand A; Sanz M; Chomienne C; Fenaux P; Dombret H;
Leukemia; 2005 Jul; 19(7):1153-60. PubMed ID: 15889156
[TBL] [Abstract][Full Text] [Related]
8. Clinical impact of FLT3 mutation load in acute promyelocytic leukemia with t(15;17)/PML-RARA.
Schnittger S; Bacher U; Haferlach C; Kern W; Alpermann T; Haferlach T
Haematologica; 2011 Dec; 96(12):1799-807. PubMed ID: 21859732
[TBL] [Abstract][Full Text] [Related]
9. Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia.
Gale RE; Hills R; Pizzey AR; Kottaridis PD; Swirsky D; Gilkes AF; Nugent E; Mills KI; Wheatley K; Solomon E; Burnett AK; Linch DC; Grimwade D;
Blood; 2005 Dec; 106(12):3768-76. PubMed ID: 16105978
[TBL] [Abstract][Full Text] [Related]
10. Internal tandem duplication and Asp835 mutations of the FMS-like tyrosine kinase 3 (FLT3) gene in acute promyelocytic leukemia.
Shih LY; Kuo MC; Liang DC; Huang CF; Lin TL; Wu JH; Wang PN; Dunn P; Lai CL
Cancer; 2003 Sep; 98(6):1206-16. PubMed ID: 12973844
[TBL] [Abstract][Full Text] [Related]
11. Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples.
Cloos J; Goemans BF; Hess CJ; van Oostveen JW; Waisfisz Q; Corthals S; de Lange D; Boeckx N; Hählen K; Reinhardt D; Creutzig U; Schuurhuis GJ; Zwaan ChM; Kaspers GJ
Leukemia; 2006 Jul; 20(7):1217-20. PubMed ID: 16642044
[TBL] [Abstract][Full Text] [Related]
12. [FLT3 internal tandem duplication in patients with acute promyelocytic leukemia].
Zhu YM; Liu YF; Zhang SJ; Shen ZX; Hu J
Zhonghua Xue Ye Xue Za Zhi; 2007 Jun; 28(6):371-4. PubMed ID: 17939400
[TBL] [Abstract][Full Text] [Related]
13. PML-RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy.
Cicconi L; Divona M; Ciardi C; Ottone T; Ferrantini A; Lavorgna S; Alfonso V; Paoloni F; Piciocchi A; Avvisati G; Ferrara F; Di Bona E; Albano F; Breccia M; Cerqui E; Sborgia M; Kropp MG; Santoro A; Levis A; Sica S; Amadori S; Voso MT; Mandelli F; Lo-Coco F
Leukemia; 2016 Oct; 30(10):1987-1992. PubMed ID: 27133819
[TBL] [Abstract][Full Text] [Related]
14. PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model.
Kelly LM; Kutok JL; Williams IR; Boulton CL; Amaral SM; Curley DP; Ley TJ; Gilliland DG
Proc Natl Acad Sci U S A; 2002 Jun; 99(12):8283-8. PubMed ID: 12060771
[TBL] [Abstract][Full Text] [Related]
15. Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype.
Poiré X; Moser BK; Gallagher RE; Laumann K; Bloomfield CD; Powell BL; Koval G; Gulati K; Holowka N; Larson RA; Tallman MS; Appelbaum FR; Sher D; Willman C; Paietta E; Stock W
Leuk Lymphoma; 2014 Jul; 55(7):1523-32. PubMed ID: 24160850
[TBL] [Abstract][Full Text] [Related]
16. Correlation between FLT3-ITD status and clinical, cellular and molecular profiles in promyelocytic acute leukemias.
Souza Melo CP; Campos CB; Dutra ÁP; Neto JC; Fenelon AJ; Neto AH; Carbone EK; Pianovski MA; Ferreira AC; Assumpcão JG
Leuk Res; 2015 Feb; 39(2):131-7. PubMed ID: 25530565
[TBL] [Abstract][Full Text] [Related]
17. Influence of bcr-3 PML-RARα transcript on outcome in Acute Promyelocytic Leukemia patients of Kashmir treated with all-trans retinoic acid and/or arsenic tri-oxide.
Baba SM; Shah ZA; Pandith AA; Dil-Afroze ; Jan A; Mir KA; Aziz SA; Ahmad Z
Cancer Genet; 2019 Feb; 231-232():14-21. PubMed ID: 30803552
[TBL] [Abstract][Full Text] [Related]
18. Treatment-influenced associations of PML-RARα mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia.
Gallagher RE; Moser BK; Racevskis J; Poiré X; Bloomfield CD; Carroll AJ; Ketterling RP; Roulston D; Schachter-Tokarz E; Zhou DC; Chen IM; Harvey R; Koval G; Sher DA; Feusner JH; Tallman MS; Larson RA; Powell BL; Appelbaum FR; Paietta E; Willman CL; Stock W
Blood; 2012 Sep; 120(10):2098-108. PubMed ID: 22734072
[TBL] [Abstract][Full Text] [Related]
19. FLT3 overexpression in acute promyelocytic leukemia patients without detectable FLT3-ITD or codon 835-836 mutations: a pilot study.
Lilakos K; Viniou NA; Mavrogianni D; Vassilakopoulos TP; Dimopoulou MN; Plata E; Angelopoulou MK; Variami E; Stavrogianni N; Liapi D; Xilouri I; Galanopoulos A; Ageloudi M; Panayiotidis P; Voulgarelis M; Rombos J; Meletis J; Yataganas X; Pangalis GA
Anticancer Res; 2006; 26(2A):1201-7. PubMed ID: 16619525
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors of patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide-based frontline therapy.
Lou Y; Ma Y; Suo S; Ni W; Wang Y; Pan H; Tong H; Qian W; Meng H; Mai W; Huang J; Yu W; Wei J; Mao L; Jin J
Leuk Res; 2015 Sep; 39(9):938-44. PubMed ID: 26183877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
